Use of rapid molecular TB diagnostics for incarcerated people in Brazil
The International Journal of Tuberculosis and Lung Disease · 2023
DOI: 10.5588/ijtld.22.0642 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2023. Verfasst von E B Fajer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis, Prisoners. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Dear Editor, In 2021, an estimated 4.2 million cases of TB remained undiagnosed.1 Reducing this gap through early diagnosis of disease and rapid detection of drug resistance is critical for managing individual outcomes and preventing onwards transmission of Mycobacterium tuberculosis.1–3 Expanding access to highly sensitive and specific rapid molecular TB diagnostics recommended by the WHO is an urgent priority for incarcerated individuals, who have a TB incidence 10 times that of the general population.4 In the Americas, TB notifications are increasingly concentrated within prisons,5,6 including in Brazil where 12.2% of the country’s notified TB cases occurred among incarcerated individuals in 2019.7 Although the National Tuberculosis Program in Brazil recently endorsed the use of Xpertw MTB/ RIF (MTB/RIF; Cepheid, Sunnyvale, CA, USA), rapid molecular diagnostics usage in prisons has not yet been measured. We therefore quantified the use of Xpert and chest radiography (CXR) among all newly diagnosed TB cases reported to Brazil’s national notifiable disease system (Sistema de Informação de Agravos de Notificação or SINAN) from January 2015 to December 2018. We excluded cases with unknown incarceration status or patients below 18 years old, as they compose a small proportion of the incarcerated population. SINAN reports diagnostic results by testing modality, including MTB/RIF, CXR, sputum smear, and culture.7 Rapid molecular diagnostics are recommended by the Brazil Ministry of Health and the WHO, but, in practice, they are not uniformly available within prisons. MTB/RIF test outcomes were reported as M. tuberculosis detected, susceptible or resistant to rifampicin; M. tuberculosis not detected; inconclusive test; or not performed. Xpert G4 (Cepheid) was primarily used during our study period; Brazil subsequently introduced Xpert Ultra (Cepheid) across the country’s laboratory network in 2019. CXR outcomes were reported as suspect, normal, other pathology, or not performed; sputum smear outcomes as positive, negative, not performed, or not applicable. Culture outcomes were reported as positive, negative, in-progress, or not performed. For each diagnostic test, we classified individuals with positive, negative, or in-progress reported results as having received that test (test usage), and individuals with tests marked not performed or missing information as having not received that test (no test usage). We compared the use of different testing modalities between incarcerated and non-incarcerated populations with two-proportion Z-tests. We assessed heterogeneity in diagnostic usage between states with v2 tests for equality of proportions. An ‘empty’ multilevel regression8 was run with state or municipality random effects and no other predictor variables to estimate intraclass correlation coefficients (ICCs) for municipality and state-level clustering, measuring the proportion of total variability as determined using cluster membership. We combined individual-level variables from SINAN with municipality-level covariates, including the 2010 average per capita household income and GINI coefficient, from Brazil’s Human Development Atlas,9 incarcerated population size from Brazil’s National Prison Information Survey,10 and total population density from the Brazilian Institute of Geography and Statistics.11 Finally, to identify locations with large diagnostic gaps, we calculated the proportions of incarcerated individuals diagnosed without MTB/RIF or CXR in the 26 municipalities with incarcerated populations over 5,000 individuals. This study was approved by the Institutional Review Board at Stanford University, Stanford, CA, USA (Protocol #50466). Between 2015 and 2018, there were 284,415 newly diagnosed TB cases reported to SINAN, including 258,014 cases among patients over 18 years old with information on incarceration status. Of these, 10.6% (27,400/258,014 cases) occurred among incarcerated individuals and 89.4% (230,614/258,014) were among the general population. We found overall MTB/RIF use of 27.5% (70,988/258,014), CXR use of 70.9% (183,058/258,014), sputum smear use of 71.5% (184,509/258,014), and culture use of 34.1% (87,905/258,014), with significant overlap in populations receiving multiple different diagnostic tests. TB patients received a mean of 2.04 diagnostic tests. Use of MTB/RIF and CXR differed significantly between Brazil’s incarcerated and non-incarcerated populations. MTB/RIF use in incarcerated individuals was greater than that in non-incarcerated individuals (36.2% vs. 26.5%, P , 0.001) each year and overall, and its use in prison settings increased over the 4 years (P , 0.001) for a positive linear trend in
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Stanford University School of Medicine, Stanford, CA, USA.
- National Tuberculosis Control Program, Brasília, DF, Brazil.
- Department of Epidemiology, School of Public Health, University of São Paulo, São Paulo, SP, Brazil.
- Central Laboratory of Public Health, Campo Grande, MS, Brazil.
- Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil, Oswaldo Cruz Foundation, Campo Grande, MS, Brazil, Yale School of Public Health, New Haven, CT, USA.
- University of Utah, Division of Epidemiology, Salt Lake City, UT, USA.
Förderung
- NIAID NIH HHS
Zitieren
APA
Fajer, E. B., Costa, F. D., Pelissari, D. M., Diaz Quijano, F. A., Coelho de Brito, A., Cunha, E. A. T., Croda, J., Andrews, J. R., & Walter, K. S. (2023). Use of rapid molecular TB diagnostics for incarcerated people in Brazil. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.22.0642
Vancouver
Fajer EB, Costa FD, Pelissari DM, Diaz Quijano FA, Coelho de Brito A, Cunha EAT, et al. Use of rapid molecular TB diagnostics for incarcerated people in Brazil. The International Journal of Tuberculosis and Lung Disease. 2023. doi:10.5588/ijtld.22.0642
BibTeX
@article{Fajer2023,
author = {Fajer, E B and Costa, F D and Pelissari, D M and Diaz Quijano, F A and Coelho de Brito, A and Cunha, E A T and Croda, J and Andrews, J R and Walter, K S},
title = {Use of rapid molecular TB diagnostics for incarcerated people in Brazil},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2023},
doi = {10.5588/ijtld.22.0642}
}
EUVIMED